AdCLD-CoV19
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,[1][2][3] a company from South Korea.[4]
References[edit]
- ^ "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers". ClinicalTrials.gov. 14 December 2020. NCT04666012. Retrieved 23 March 2021.
- ^ Chan-Hyuk, Kim (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.
- ^ Chan-hyuk, Kim (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.
- ^ Cellid Co Ltd, Company Profile and News, Bloomberg Markets.
 |
Scholia has a profile for AdCLD-CoV19 (Q108415181). |
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |